SCHEMBL6320213

SCHEMBL6320213

Cc1[nH]c2ccc(C(=O)NS(=O)(=O)c3ccc(Br)s3)cc2c1Cc1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 3/20 0.39
SCN9A Q15858 3/20 0.39
MAPT P10636 5/20 0.38
EPHX2 P34913 2/20 0.37
NR1H4 Q96RI1 2/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
MCL1 Q07820 3/20 0.35
PTGS2 P35354 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
PPARG P37231 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319329 0.92 PPARG (0.42) SCN5ASCN9AMAPTEPHX2NR1H4
SCHEMBL6318799 0.90 MAPT (0.41) MAPTMCL1PTGS2KMT2AHDAC1
SCHEMBL6320869 0.90 MAPT (0.41) MAPTPTGS2MEN1ALDH1A1LMNA
SCHEMBL6318323 0.86 MAPT (0.43) SCN9AMAPTMCL1PTGS2HDAC3
SCHEMBL6135287 0.85 SCN5A (0.42) SCN5ASCN9AMAPTEPHX2NR1H4
SCHEMBL5882187 0.83 MAPT (0.41) MAPTPTGS2MEN1ALDH1A1LMNA
SCHEMBL5881728 0.81 FLT1 (0.43) SCN5AEPHX2NR1H4PTGS2HDAC3
SCHEMBL6320424 0.81 SCN5A (0.39) SCN5ASCN9AMAPTEPHX2NR1H4
SCHEMBL6319584 0.81 MAPT (0.42) MAPTEPHX2MCL1PTGS2MEN1
SCHEMBL6320284 0.80 MAPT (0.40) MAPTMCL1MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP claimed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A SCN5A 59/4885SCN9A 1847/4885MAPT 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.